Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion.
CLINICAL TRIALS
DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
DRUG TOXICITY
OMERACT
PATIENT SATISFACTION
RISK
Journal
The Journal of rheumatology
ISSN: 0315-162X
Titre abrégé: J Rheumatol
Pays: Canada
ID NLM: 7501984
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
accepted:
31
01
2019
pubmed:
17
2
2019
medline:
21
10
2020
entrez:
17
2
2019
Statut:
ppublish
Résumé
The Outcome Measures in Rheumatology (OMERACT) Safety Working Group is identifying core safety domains that matter most to patients with rheumatic disease. International focus groups were held with 39 patients with inflammatory arthritis to identify disease-modifying antirheumatic drug (DMARD) experiences and concerns. Themes were identified by pragmatic thematic coding and discussed in small groups by meeting attendees. Patients view DMARD side effects as a continuum and consider the cumulative effect on day-to-day function. Disease and drug experiences, personal factors, and life circumstances influence tolerance of side effects and treatment persistence. Patients weigh overall adverse effects and benefits over time in relation to experiences and life circumstances.
Identifiants
pubmed: 30770516
pii: jrheum.181185
doi: 10.3899/jrheum.181185
pmc: PMC6697626
mid: NIHMS1030736
doi:
Substances chimiques
Antirheumatic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1168-1172Subventions
Organisme : NIAMS NIH HHS
ID : P30 AR070254
Pays : United States
Références
Scand J Occup Ther. 2010 Dec;17(4):326-34
pubmed: 20001643
J Clin Epidemiol. 2014 Jul;67(7):745-53
pubmed: 24582946
J Rheumatol. 2017 Dec;44(12):1916-1919
pubmed: 27744393
Rheumatology (Oxford). 2004 May;43(5):583-6
pubmed: 14970399
Drug Saf. 2013 Dec;36(12):1129-49
pubmed: 24092596
JAMA Oncol. 2015 Nov;1(8):1051-9
pubmed: 26270597
N Engl J Med. 2010 Mar 11;362(10):865-9
pubmed: 20220181
Rheumatology (Oxford). 2011 Jan;50(1):152-60
pubmed: 20871128
J Rheumatol. 2015 Mar;42(3):379-85
pubmed: 25512473
Expert Opin Drug Saf. 2018 May;17(5):475-486
pubmed: 29505325